GE HealthCare's Latest Product Launch to Boost Cardiology Care

GEHC further stated that the FDA approved Flyrcado for patients with known or suspected CAD in 2024. This is expected to deliver higher diagnostic efficacy, unlike SPECT MPI, the predominant procedure used in nuclear cardiology at present. GE HealthCare's management believes that the launch of Flyrcado represents a significant advancement in cardiac care, providing a new, highly effective diagnostic tool for those with known or suspected CAD. Additionally, Flyrcado has been granted traditional pass-through ...